Breaking News! China's First Ovarian Cancer Methylation Test Approved for Market
Beijing Origin CISPOLY Biotechnology Co., Ltd. (hereinafter "CISPOLY") announced that its independently developed "Human CDO1 and HOXA9 Gene Methylation Detection Kit (PCR-Fluorescent Probe Method)" (trade name: CISOVA®) has officially received a Class III medical device registration certificate from the National Medical Products Administration (Registration No.: 20253402443). As the first approved ovarian cancer methylation detection product, CISOVA® fills a technological void in clinical ovarian cancer detection, providing an important tool for early detection and precision diagnosis of ovarian cancer.
CISPOLY has always focused on the prevention and treatment needs of Chinese women's tumors, committed to advancing innovation and translation of molecular diagnostic technology. With the approval of CISOVA®, CISPOLY's women's tumor methylation detection product matrix has achieved comprehensive coverage of the three major gynecologic cancers — CISCER® (cervical cancer), CISENDO® (endometrial cancer), and CISOVA® (ovarian cancer), with all three registration certificates in place. This milestone marks CISPOLY's complete strategic layout and leading advantage in the field of early diagnosis and treatment of gynecologic tumors, further contributing to the advancement of women's health management in China.
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology enterprise driven by innovative science and focused on health. CISPOLY is a pioneer in the field of early diagnosis of gynecologic tumors. With proprietary technology and patent-protected biomarkers at its core, the company has developed early diagnostic products for cervical cancer, endometrial cancer, ovarian cancer, and other gynecologic tumors, filling a void in this field.
As women pay increasing attention to their own health, the women's health market holds great promise. Beyond its gynecologic tumor early screening and diagnosis product line, CISPOLY will continue to build additional women's health-related product pipelines, striving to become a technology-innovation-driven leader in the women's health market.